💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

I think STRIDE helps us here because among the various drugs for diabetes, if your patient has PAD, you might prioritize a GLP-1 receptor agonist, or specifically semaglutide, based on the results ...

We all know that Ozempic, a GLP-1 receptor agonist medication, also called semaglutide, causes weight loss. On average, high-dose semaglutides, like in Wegovy, cause people to lose somewhere ...

Ozempic is a brand-name medication containing the active ingredient semaglutide. It belongs to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 agonists). It mimics the ...

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

Oral semaglutide reduced risk for cardiovascular events in people with type 2 diabetes, atherosclerotic CVD and kidney disease. It is now the first and only oral GLP-1 receptor agonist with proven ...

Oral semaglutide (Rybelsus; Novo Nordisk) taken once daily cut the risk of cardiovascular mortality, nonfatal MI, or nonfatal stroke in the trial by 14% after a mean follow-up of 47.5 months, a ...